James Thompson
Family Medicine · Lenoir, NCNPI 1760422620
Payments from drug & device makers
Across 116 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$423
- AbbVie$218
- Pfizer$189
- AstraZeneca$162
- Lilly USA, LLC$130
- Amgen$75
- plus $516 from 18 others
What the payments were for
- Food & beverage$1,713100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $423 |
| AbbVie(2 entities) | 14 | $218 |
| Pfizer | 14 | $189 |
| AstraZeneca | 11 | $162 |
| Lilly USA, LLC | 9 | $130 |
| Amgen | 4 | $75 |
| GSK | 4 | $66 |
| Exact Sciences | 3 | $46 |
| Dexcom, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Inari Medical, Inc. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 3 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $34 |
| Mylan Specialty L.p. | 2 | $28 |
| Astellas Pharma US Inc | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Abbott | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
$1,713 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $39,810 |
| OzempicSemaglutide | 31 | $35,727 |
| JanuviaSitagliptin Phosphate | 38 | $28,558 |
| JardianceEmpagliflozin | 16 | $25,720 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,446 |
| FarxigaDapagliflozin Propanediol | 22 | $20,219 |
| MounjaroTirzepatide | 19 | $19,846 |
| XareltoRivaroxaban | 20 | $16,671 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $14,263 |
| TrulicityDulaglutide | 13 | $12,021 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,910 |
| LinzessLinaclotide | 16 | $8,550 |
| KerendiaFinerenone | 11 | $7,058 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,634 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $39,81029 claims |
| Novo NordiskOzempic | $423 | $35,72731 claims |
| Lilly USA, LLCMounjaro, Trulicity | $130 | $31,86732 claims |
| AstraZenecaFarxiga, Symbicort | $162 | $29,12958 claims |
| Boehringer IngelheimJardiance | $15 | $25,72016 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $66 | $12,85526 claims |
| AbbVieLinzess, Synthroid | $218 | $9,60729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Lenoir
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.